Compare · INCR vs MRK
INCR vs MRK
Side-by-side comparison of Intercure Ltd. (INCR) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INCR and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $358.41B, about 5273.2x INCR ($68.0M).
- Over the past year, INCR is down 33.8% and MRK is up 59.8% - MRK leads by 93.6 points.
- MRK has hit the wire 11 times in the past 4 weeks while INCR has been quiet.
- MRK has more recent analyst coverage (25 ratings vs 1 for INCR).
- Company
- Intercure Ltd.
- Merck & Company Inc.
- Price
- $5.03-5.45%
- $140.65-3.18%
- Market cap
- $68.0M
- $358.41B
- 1M return
- -11.91%
- -5.46%
- 1Y return
- -33.82%
- +59.82%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 11
- Recent ratings
- 1
- 25
Intercure Ltd.
InterCure Ltd, together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest INCR
- SEC Form 6-K filed by Intercure Ltd.
- InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Amendment: SEC Form 6-K/A filed by Intercure Ltd.
- SEC Form 6-K filed by Intercure Ltd.
- SEC Form 4 filed by Chief Financial Officer Cohen Amos
- SEC Form 6-K filed by Intercure Ltd.
- InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages
- SEC Form D filed by Intercure Ltd.
- InterCure Ltd. Announces 1-for-5 Reverse Share Split
- SEC Form 6-K filed by Intercure Ltd.
Latest MRK
- KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
- Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
- A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
- Amendment: SEC Form 3/A filed by Merck & Company Inc.
- Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
- Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
- SEC Form 8-K filed by Merck & Company Inc.
- Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
- Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
- Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026